Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
01 September 2022Website:
http://www.bioaffinitytech.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 20 Nov 2024 14:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
BIAF Latest News
JERSEY CITY, N.J. , Oct. 21, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has closed its previously announced registered direct offering with institutional investors for the purchase and sale of 2,048,294 shares (the "Shares") of common stock at a price of $1.30 per share and concurrent private placement of common warrants (the "Warrants") to purchase up to 2,662,782 shares of common stock at an exercise price of $1.50 per common share for gross proceeds of $2,662,782 before deducting placement agent fees and other offering expenses payable by the Company.
JERSEY CITY, N.J. , Aug. 5, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that in connection with the BioAffinity Technologies (NASDAQ: BIAF) warrant exercise agreements dated August 2, 2024, with three existing accredited investors, such accredited investors have exercised outstanding warrants to purchase an aggregate of 1,041,667 of the Company's shares of common stock (the "Existing Warrants") at an exercise price that was reduced from $1.64 to $1.25 per share, for gross cash proceeds of approximately $1,302,083 and in consideration of such exercise, the exercising holders received in a private placement new unregistered warrants (the "New Warrants") to purchase up to an aggregate of 1,302,083 shares of common stock (equal to 125% of the shares of common stock issued in connection with the exercise of the Existing Warrants).
JERSEY CITY, N.J. , Aug. 2, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF) (the "Company") has entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 1,041,667 of the Company's shares of common stock (the "Existing Warrants").
What type of business is bioAffinity Technologies?
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
What sector is bioAffinity Technologies in?
bioAffinity Technologies is in the Healthcare sector
What industry is bioAffinity Technologies in?
bioAffinity Technologies is in the Diagnostics & Research industry
What country is bioAffinity Technologies from?
bioAffinity Technologies is headquartered in United States
When did bioAffinity Technologies go public?
bioAffinity Technologies initial public offering (IPO) was on 01 September 2022
What is bioAffinity Technologies website?
https://www.bioaffinitytech.com
Is bioAffinity Technologies in the S&P 500?
No, bioAffinity Technologies is not included in the S&P 500 index
Is bioAffinity Technologies in the NASDAQ 100?
No, bioAffinity Technologies is not included in the NASDAQ 100 index
Is bioAffinity Technologies in the Dow Jones?
No, bioAffinity Technologies is not included in the Dow Jones index
When was bioAffinity Technologies the previous earnings report?
No data
When does bioAffinity Technologies earnings report?
Next earnings report date is not announced yet